Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil Versus Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy in Premenopausal Women with Axillary Node-Positive Operable Breast Cancer: Results of a Randomized Trial

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 35-45

  Coombes, R C ^a   Bliss, J M ^b   Wils, J ^b   Morvan, F ^b   Espie M ^b   Amadori, D ^b   Gambrosier, P ^b   Richards, M ^b   Aapro, M ^b   Villar Grimalt, A ^b   McArdle, C ^b   Perez Lopez F R ^b   Vassilopoulos, P ^b   Pinto Ferreira, E ^b   Chilvers, C E D ^b   Coombes, G ^b   Woods, E M ^b   Marty, M ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ALOPECIA; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; ALOPECIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; METHOTREXATE; MIDDLE AGED; NAUSEA; PREMENOPAUSE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; VOMITING;

EID: 0030068274     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.35     Document Type: Article

References (28)

1. Brincker H, Mouridsen HT, Anderson KW: Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat 3:91-95, 1983
2. Wolmark N, Fisher B: Adjuvant chemotherapy in stage II breast cancer: A brief overview of the NSABP clinical trials. World J Surg 9:699-706, 1985
3. Bonadonna G, Valagussa P, Rossi A, et al: Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5:95-115, 1985
4. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
5. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metatastic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987
6. Tormey DC, Weinberg VE, Leone LA, et al: A comparison of intermittent vs continuous and of Adriamycin vs methotrexate 5-drug chemotherapy for advanced breast cancer: A Cancer and Leukemia Group B study. Am J Clin Oncol 7:231-239, 1984
7. Buzdar AU, Gutterman JU, Blumenschein GR, et al: Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 41:1064-1075, 1978
8. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91:710-717, 1979
9. Arcamone F, Penco S, Vigevoni A, et al: Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18:703-707, 1975
10. Villani F, Favalli L, Piccinini F: Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4'-epi-doxorubicin in guinea pig heart muscle. Tumori 66:689-697, 1980
11. Jain KK, Casper ES, Geller NL, et al: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 3:818-826, 1985
12. Italian Multicentre Breast Study With Epirubicin: Phase III randomized study of fluorouracil, epirubicin and cyclophosphamide versus fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: An Italian multicenter trial. J Clin Oncol 6:976-982, 1988
13. Focan C, Andrien JM, Closon MTh. et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993
14. Bliss JM, Heath E, Bryant TN, et al: Improving the quality of data in clinical trials in cancer. Br J Cancer 63:412-415, 1991
15. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomised clinical trials requiring prolonged observation of each patient: II analysis and examples. Br J Cancer 35:1-39, 1977
16. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
17. Collins R, Gray R, Godwin J, et al: Avoidance of large biases and large random errors in the assessment of moderate treatment effects: The need for systematic overviews. Stat Med 6:245-250, 1987
18. Misset JL, Gil-Delgado M, Chollet Ph, et al: Ten year results of the French trial comparing Adriamycin, vincristine, 5-fluorouracil and cyclophosphamide to standard CMF as adjuvant therapy for node positive breast cancer. Proc Am Soc Clin Oncol 11:54, 1992 (abstr 41)
19. Fisher B, Redmond C, Wickerham DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer. The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989
20. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
21. Carpenter JT, Velez-Garcia E, Aron BS, et al: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: A Southeastern Cancer Study Group study. Proc Am Soc Clin Oncol 13:66, 1994 (abstr 68)
22. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991
23. Brandi M, De Nitrio A, Ditonno P, et al: Oral versus intravenous CMF in metastatic breast cancer: A randomized trial. Int J Oncol 4/3:559-565, 1994
24. De Bruijn EA, Slee PT Th, Van Oosterom AT, et al: Pharmacokinetics of intravenous and oral cyclophosphamide in the presence in methotrexate and fluorouracil. Pharm Weekbl [Sci] 10:200-206, 1988
25. Marty M: Epirubicin and the risk of leukemia: Not substantiated? J Clin Oncol 11:1431-1432, 1993
26. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al: Acute monocytic or myelomonocytic leukaemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol 10:1444-1451, 1992
27. Ragaz J, Yun J, Spinelli J: Analysis of incidence of secondary acute myelogenous leukemias (2ndAML) in breast cancer patients (BCP) treated with adjuvant therapy (AT) - Association with therapeutic regimens. Proc Am Soc Clin Oncol 14:86, 1995 (abstr 147)
28. Robert J: Epirubicin: Clinical pharmacology and dose-effect relationship. Drugs 45:20-30, 1993 (suppl 2)